Landing AI Announces Software Licensing Agreement with Ligand Pharmaceuticals Incorporated

The OmniAb antibody discovery platform provides Ligand's biopharmaceutical industry partners access to the world's most advanced antibody repertoires and screening technologies to enable unparalleled discovery of next-generation therapeutics.

Fremont, CA: Landing AI announced a software licensing agreement with Ligand Pharmaceuticals Incorporated to incorporate LandingLens into Ligand's OmniAb® and xPloration™ antibody discovery platforms. LandingLens is a software platform that provides an end-to-end workflow to build, iterate and operationalize AI-powered visual inspection solutions.

"Landing AI, under the leadership of world-renowned AI pioneer Andrew Ng, is a proven and trusted partner in empowering their customers to realize the business value of computer vision," says Bob Chen, Ph.D., Director, Systems Engineering with Ligand Pharmaceuticals. "We selected Landing AI because of the company's unique data-centric approach that puts getting high-quality data at the heart of AI development. Notably, the LandingLens software platform provides a host of specifically designed data preparation tools and capabilities that allow us to generate accurate and consistent datasets that we can iterate over time to continuously improve our existing AI systems."

The new AI-driven tools further improve Ligand's high-throughput single B cell screening accuracy and throughput in various complex biological assays, potentially increasing the yield of antibodies with desirable properties in even less time.

"AI and deep learning have emerged as powerful technologies to enable a variety of vision-based applications. We are excited to enter into this partnership with Ligand Pharmaceuticals and are committed to offering the best tools to help our customers unlock the promise of AI," said John Reuter, Vice President of Sales at Landing AI.